NCT05556863View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

ELA026

Single dose of ELA026

DRUG

ELA026

Multiple doses of ELA026

Trial Locations (2)

68502

Celerion, Lincoln

Unknown

Medical University of Vienna, Vienna

Sponsors
All Listed Sponsors
lead

Electra Therapeutics Inc.

INDUSTRY